Sai Life Sciences Ltd (SAILIFE) Q1 FY27 Results Analysis: PAT Jumps 21%, Finance Costs Plunge 38%

Cofacto Research Updated August 07, 2026 2 min read

Negative

Sai Life Sciences Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 554.29 Cr (+11.66% YoY) and PAT growth of +21.22% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	August 06, 2026
Quarter	Q1 FY 2026-2027
Revenue (Q1)	Rs. 554.29 Cr (+11.66% YoY)
PAT (Q1)	Rs. 73.28 Cr (+21.22% YoY)
EBITDA margin	26.70% (+234 bps YoY)
EPS (Q1)	Rs. 3.46 (+19.31% YoY)
Market cap	Rs. 30,007.89 Cr
CMP	Rs. 1,413.50

Quarter Snapshot

Revenue grew 11.66% YoY but missed management's 15-20% CAGR guidance; EBITDA margin at 26.70% was also below the 28-30% target. PAT grew 21.22% YoY and finance costs declined 38% on debt repayment, but lumpy revenue and QoQ margin compression remain challenges. Capacity expansion catalysts are pending.

Key Investment Insights

Key Positives

Revenue grew 11.66% YoY to Rs.554.29 Cr.
EBITDA margin expanded 234 bps YoY to 26.70%.
PAT grew 21.22% YoY to Rs.73.28 Cr.
Finance costs declined 38.22% YoY to Rs.7.64 Cr due to debt repayment.
EBITDA growth (22.39% YoY) outpaced revenue growth (11.66% YoY).
No exceptional items in Q1FY27; normalized PAT equals reported PAT.

Risk Factors

Revenue growth of 11.66% YoY is below management's 15-20% CAGR guidance corridor.
EBITDA margin of 26.70% is below the sustained target band of 28-30%.
Sequential revenue declined 7.95% QoQ, confirming lumpy revenue pattern.
QoQ EBITDA margin compressed 262 bps, driven by employee cost share rising 146 bps QoQ.